Compass Pathways/$CMPS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Ticker
$CMPS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
166
ISIN
US20451W1018
Website
Compass Pathways Metrics
BasicAdvanced
$330M
-
-$1.94
2.28
-
Price and volume
Market cap
$330M
Beta
2.28
52-week high
$8.54
52-week low
$2.25
Average daily volume
3.9M
Financial strength
Current ratio
10.183
Quick ratio
8.671
Long term debt to equity
11.159
Total debt to equity
16.388
Interest coverage (TTM)
-36.14%
Profitability
EBITDA (TTM)
-162.595
Effective tax rate (TTM)
-1.27%
Management effectiveness
Return on assets (TTM)
-32.40%
Return on equity (TTM)
-60.62%
Valuation
Price to book
1.68
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
-1.807
Free cash flow yield (TTM)
-55.34%
Free cash flow per share (TTM)
-195.34%
Growth
Earnings per share change (TTM)
-15.40%
3-year earnings per share growth (CAGR)
0.08%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Bulls say / Bears say
Compass Pathways' COMP360 psilocybin therapy has received Breakthrough Therapy designation from the FDA, indicating significant potential for treating treatment-resistant depression. (stocktitan.net)
The company maintains a strong cash position of $165.1 million as of December 31, 2024, with an additional $140.4 million raised in Q1 2025, providing ample resources for ongoing clinical trials. (stocktitan.net)
Analysts have assigned a consensus 'Buy' rating to CMPS, with an average 12-month price target of $20.20, suggesting substantial upside potential. (defenseworld.net)
Compass Pathways reported a net loss of $155.1 million for 2024, an increase from $118.5 million in 2023, raising concerns about financial sustainability. (stocktitan.net)
The company's COMP005 trial for treatment-resistant depression experienced delays, with top-line data now expected in Q2 2025, potentially impacting investor confidence. (markets.businessinsider.com)
Despite positive analyst ratings, the stock's current price of $3.38 is significantly below the average target price, indicating potential market skepticism. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Compass Pathways News
AllArticlesVideos
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
Proactive Investors·3 weeks ago
Compass Pathways' depression drug succeeds late-stage trial
Reuters·3 weeks ago
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $330M as of July 11, 2025.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of July 11, 2025.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.